Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

5:15 p.m 11/10 INO-5401 and INO-9012 Delivered Intramuscularly (IM) with Electroporation (EP) in Combination with Cemiplimab (REGN2810) in Newly Diagnosed Glioblastoma
David A. Reardon, MD – Dana-Farber Cancer Institute

5:25 p.m. Panel Discussion
Moderator: Giovanni Melillo, MD – AstraZeneca
Panelists: Jonathan Cheng, MD – Bristol Myers Squibb
Sandra Demaria, MD – Weill Cornell Medicine
Lawrence G. Lum, MD, DSc – University of Virginia
David A. Reardon, MD – Dana-Farber Cancer Institute

Session III: Novel Combinations
4:45–6:00 p.m. EST
Wednesday, Nov. 10, 2021*
2–6 p.m. EST
Independence Ballroom (Marriott Marquis)

Learning Objectives
At the conclusion of this activity, participants should be able to:

Outline the role of immune cells other than T cells in anti-cancer immunity
Summarize the state of CAR T application in solid tumors and future directions for this field
Discuss the rational combination of immunotherapies with other anti-cancer modalities to improve patient outcomes

The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations is supported in part by grants from Bristol Myers Squibb and Genentech, Inc.

https://www.sitcancer.org/2021/program/pre-conference-programs/industryprogram

“We're very pleased, as you say it, being able to present our data later this week at the pre -conference symposium at the SITC meeting, where Dave Reardon will be presenting the OS24 data, again, with some updated immunology and some tissue-based data which we're particularly excited. I think utilizing those data, along with what we've known before -- again, we previously demonstrated median overall survival in our MGMT-unmethylated population that's been higher than what we would've expected with respect to historical controls, and we still have yet to have reached median overall survival in our MGMT - methylated patients. That's a good thing that we haven't met that median yet. Pending those data, we'll really make decisions as to where we can bring this opportunity forward but in general, we're very encouraged by what certainly the key opinion leaders and the scientists and clinicians are telling us in this space. We're very encouraged by the fact that again, we have the opportunity to present at a peer-reviewed scientific meeting. And so I look forward to next opportunities specifically for 5401 in the GBM” Dr. Jeffrey Skolnik